The organ transplantation system is viewed as one of our most equitable health care services, but poor patients are effectively excluded by policy that denies Medicaid coverage of post-transplant immunosuppressant medication.

A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.

Reasons for the shortage of primary care physicians in regions designated as Health Professional Shortage Areas and steps that medical schools and state and federal policymakers can take to alleviate the shortage.

The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition.

In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013.

Overall utilization of the few biosimilars currently available to patients has been limited.

Physicians face challenges in getting reimbursed for the care they provide to immigrants.

Disparities in children’s mental health care could be addressed through expansion of school-based programs via passage of the Mental Health in Schools Act.

Two physicians examine the history of cancer drug pricing and the barriers to setting fair prices for life-saving cancer medications.

A physician argues that cost should not be a major consideration in a hospital's decision to provide palliative care services to patients.